Publications by A C Abramo

Publications by authors named "A C Abramo"

Lancet Infect Dis

January 2025

Monaldi Arch Chest Dis

October 2024

Biological drugs have transformed severe asthma treatment, making remission an achievable goal, while the rise of autoimmune diseases suggests the need for combined therapies.
A review of 26 retrospective studies analyzed real-life cases where asthmatic patients also received treatment for other immune-mediated inflammatory diseases (IMIDs) using monoclonal antibodies.
The findings highlight the importance of these dual therapies in managing uncontrolled severe asthma, indicating a need for more research to evaluate their safety and effectiveness.

Travel Med Infect Dis

November 2024

From August to November 2023, Italy reported 82 local cases of Dengue virus (DENV), with 10 cases specifically studied in Rome, showcasing a shift toward local transmission of the disease.
The affected patients, mostly middle-aged and presenting classic dengue symptoms, were confirmed to have the virus through various laboratory tests including detection of DENV proteins and antibodies.
The study emphasizes the importance of developing better surveillance and diagnosis strategies for DENV infections in non-endemic regions, to manage and understand the clinical progression of the disease.

Emerg Infect Dis

September 2024

The 2022 global mpox outbreak was mainly spread through human-to-human transmission, but it's unclear how sexual relationships specifically contribute to this transmission.
Researchers studied sexual transmission of mpox by analyzing clinical samples from 15 MPXV-positive patients in Italy, using a specific marker to indicate ongoing viral replication.
Findings showed that the highest risk of infectivity came from skin lesions, and close or skin-to-skin contact during sex is the primary mode of transmission, with semen playing a much smaller role.

Vaccines (Basel)

July 2024

The study focused on the effectiveness of tixagevimab/cilgavimab (T/C) as pre-exposure prophylaxis (PrEP) in immunocompromised individuals, categorizing them into groups based on their COVID-19 history.
A total of 231 participants were included, with a significant portion having hematological diseases and receiving multiple vaccine doses; breakthrough infections (BTIs) occurred in 56 participants (24%) but were mostly mild to moderate.
Immune markers were measured over time, showing an initial increase in anti-RBD IgG antibodies at 3 months, a decline at 6 months, and low neutralizing antibodies, reinforcing T/C's clinical efficacy in reducing severe COVID-19